By Polly Ticks • Friday, November 20, 2026
Lawmakers from both parties and both chambers are asking congressional leaders to extend two federal diabetes programs before their current authorization period ends December 31. The November 19 letter calls for a multiyear renewal of the Special Diabetes Program and the Special Diabetes Program for Indians. It is a request for legislative action, rather than an announcement that Congress has approved an extension. The deadline is independently reflected in the programs’ governing funding provisions.
Senators Jeanne Shaheen and Susan Collins helped lead the appeal with House Diabetes Caucus co-chairs Diana DeGette and Gus Bilirakis. The signed letter is addressed to House Speaker Mike Johnson, House Democratic Leader Hakeem Jeffries, Senate Republican Leader John Thune and Senate Democratic Leader Chuck Schumer. Its bipartisan signatures establish support for taking up the issue, but they do not themselves establish agreement on legislative language, an extension’s duration or a floor schedule.
The two programs have distinct responsibilities. The National Institute of Diabetes and Digestive and Kidney Diseases describes the research component as a special appropriation supporting prevention and treatment research related to type 1 diabetes and its complications. It supplements research financed through regular NIH appropriations. The Indian Health Service component supports diabetes prevention and treatment through Indian Health Service, Tribal and urban Indian health programs. Treating them as interchangeable would obscure who receives the funding and what it supports.
The current statutory text for the type 1 research program provides $200 million for fiscal year 2026 and $50,410,959 for October 1 through December 31, 2026. Those amounts are specified for different periods and should not be described as two competing annual funding levels. The Indian program’s statute contains corresponding amounts. Both provisions say the appropriated money remains available until expended, a qualification that matters when discussing what the December date means for already appropriated funds.
The lawmakers argue that a longer renewal would make research planning and delivery of prevention services more predictable. That is their policy case for congressional action. An HHS performance report independently identifies December 31 as the Indian program’s extension date. NIDDK’s program description also documents support for collaborative research networks, clinical trials and shared research resources. Those continuing activities help explain the planning issue, while neither agency document establishes that the November renewal request has already been granted.
The next concrete milestones are introduced or negotiated extension language, votes in both chambers where required, and enactment. Readers can judge those events against the date and amounts in the law rather than assuming a supportive letter changes funding authority. For now, the new development is a documented bipartisan push for a multiyear extension, with roughly six weeks remaining before the current authorized period concludes and no completed renewal established by the records reviewed.
Sources
FOLLOW THE ENTIRE CREW
Daily reporting and newsroom updates from FrontPage Crew.
